References
- Cairns V, Godwin J. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol. 2005 Dec;34(6):1340–1345. doi:https://doi.org/10.1093/ije/dyi129.
- Shapiro ED, Dattwyler R, Nadelman RB, et al. Response to meta-analysis of Lyme borreliosis symptoms. Int J Epidemiol. 2005 Dec;34(6):1437–1439. author reply 1440-3. doi:https://doi.org/10.1093/ije/dyi241.
- Stricker RB, Lautin A, Burrascano JJ. Lyme disease: point/counterpoint. Expert Rev Anti Infect Ther. 2005 Apr;3(2):155–165. doi:https://doi.org/10.1586/14787210.3.2.155.
- Uhde M, Ajamian M, Li X, et al. Expression of C-reactive protein and serum amyloid A in early to late manifestations of Lyme disease. Clin Infect Dis. 2016 Dec 1;63(11):1399–1404. doi:https://doi.org/10.1093/cid/ciw599.
- Aucott JN, Soloski MJ, Rebman AW, et al. CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol. 2016 Sep 6;23(9):757–766. doi:https://doi.org/10.1128/CVI.00071-16.
- Coughlin JM, Yang T, Rebman AW, et al. Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. J Neuroinflammation. 2018 Dec 19;15(1):346. doi:https://doi.org/10.1186/s12974-018-1381-4.
- Strle K, Stupica D, Drouin EE, et al. Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans. Clin Infect Dis. 2014 Feb;58(3):372–380. doi:https://doi.org/10.1093/cid/cit735.
- Stricker RB, Johnson L. Borrelia burgdorferi aggrecanase activity: more evidence for persistent infection in Lyme disease. Front Cell Infect Microbiol. 2013 Aug 14;3:40. doi:https://doi.org/10.3389/fcimb.2013.00040.
- Nemeth J, Bernasconi E, Heininger U, et al. For the Swiss society for infectious diseases and the Swiss society for neurology. Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016 Dec 5;146:w14353. PMID: 27922168. doi:https://doi.org/10.4414/smw.2016.14353.
- Sapi E, Kasliwala RS, Ismail H, et al. The long-term persistence of Borrelia burgdorferi antigens and DNA in the tissues of a patient with Lyme disease. Antibiotics (Basel). 2019 Oct 11;8(4):183. doi:https://doi.org/10.3390/antibiotics8040183.
- López D, Vlamakis H, Kolter R. Biofilms. Cold Spring Harb Perspect Biol. 2010 Jul;2(7):a000398. doi:https://doi.org/10.1101/cshperspect.a000398.
- Qiu CC, Caricchio R, Gallucci S. Triggers of autoimmunity: the role of bacterial infections in the extracellular exposure of lupus nuclear autoantigens. Front Immunol. 2019 Nov 8;10:2608. doi:https://doi.org/10.3389/fimmu.2019.02608.
- Rebman AW, Bechtold KT, Yang T, Mihm EA, Soloski MJ, Novak CB, Aucott JN. The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome. Front Med (Lausanne). 2017 Dec 14;4:224. doi:https://doi.org/10.3389/fmed.2017.00224.
- Eikeland R, Mygland Å, Herlofson K, et al. Risk factors for a non-favorable outcome after treated European neuroborreliosis. Acta Neurol Scand. 2013 Mar;127(3):154–160. doi:https://doi.org/10.1111/j.1600-0404.2012.01690.x.
- US Centers for Disease Control and Prevention. Post-Treatment Lyme Disease Syndrome; [cited 2021 Oct 18]. Available from: https://www.cdc.gov/lyme/postlds/index.html
- Zhang S, Chen DC. Facing a new challenge: the adverse effects of antibiotics on gut microbiota and host immunity. Chin Med J (Engl). 2019 May 20;132(10):1135–1138. doi:https://doi.org/10.1097/CM9.0000000000000245.
- Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the infectious diseases society of America, American academy of neurology, and American college of rheumatology: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Neurology. 2021 Feb 9;96(6):262–273. doi:https://doi.org/10.1212/WNL.0000000000011151.
- National Institute for Health and Care Excellence. Lyme disease. NICE guideline [NG95]. 2018. [cited 2021 Dec 9]. Available from: www.nice.org.uk/guidance/ng95
- Weitzner E, McKenna D, Nowakowski J, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015 Dec 15;61(12):1800–1806. doi:https://doi.org/10.1093/cid/civ735.
- Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002 Dec;21(6):495–505. doi:https://doi.org/10.1080/07315724.2002.10719248.
- Fiala M, Halder RC, Sagong B, et al. ω-3 supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J. 2015 Jul;29(7):2681–2689. doi:https://doi.org/10.1096/fj.14-264218.
- Gröber U, Kisters K, Schmidt J. Neuroenhancement with vitamin B12—underestimated neurological significance. Nutrients. 2013 Dec 12;5(12):5031–5045. doi:https://doi.org/10.3390/nu5125031.
- Zhou D, Jiang Y. Sirtuin 3 attenuates neuroinflammation-induced apoptosis in BV-2 microglia. Aging (Albany NY). 2019 Oct 20;11(20):9075–9089. doi:https://doi.org/10.18632/aging.102375.
- Yin K, Agrawal DK. Vitamin D and inflammatory diseases. J Inflamm Res. 2014 May 29;7:69–87. doi:https://doi.org/10.2147/JIR.S63898.
- Den H, Dong X, Chen M, et al. Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment — a meta-analysis of randomized controlled trials. Aging (Albany NY). 2020 Feb 15;12(4):4010–4039. doi:https://doi.org/10.18632/aging.102810.
- Shokryazdan P, Faseleh Jahromi M, Navidshad B, et al. Effects of prebiotics on immune system and cytokine expression. Med Microbiol Immunol. 2017 Feb;206(1):1–9. doi:https://doi.org/10.1007/s00430-016-0481-y.
- Labuschagne IL, Blaauw R. An anti-inflammatory approach to the dietary management of multiple sclerosis: a condensed review. S Afr J Clin Nutr. 2018;31(3):67–73. doi:https://doi.org/10.1080/16070658.2018.1465652.